1 minute reading time (143 words)

Improving Outcomes in Hodgkin Lymphoma With Louis Diehl, MD

Hodgkin lymphoma (HL) is a rare malignancy of the lymph nodes and lymphatic system, with about 8,830 new cases diagnosed each year in the United States (Siegel et al, 2021). While the advent of novel therapies is leading to significantly improved outcomes, HL treatment continues to be associated with an increased risk for secondary cancers and cardiovascular disease (NCCN, 2021; Kreissl et al, 2020). In order to minimize long-term treatment effects and maximize health-related quality of life for patients with HL, clinicians need to stay abreast of newly established recommendations and evolving data. In this activity, Louis F. Diehl, MD, will update clinicians on developing evidence-based HL management plans tailored to individual patients and their long-term care needs. 

Related Posts

Copyright © 2022 Oncology Data Advisor. All rights reserved.